explore -WSS

explore

author：leisure time 2025-09-07 13:59:18 - browse：8877

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Lawsuit challenges CMS nursing home minimum staffing rule

WSS

Former Pear Therapeutics executives start new VC firm

People can get long Covid without testing positive for virus: Study

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Guardant Health colon cancer test endorsed by FDA advisory panel

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Vivek Ramaswamy made waves in the debate, much as in biotech

hotspot

explore

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Abortion policy in the spotlight at Republican debate

Tori Bowie and the unacceptable rates of Black maternal death

As obesity drug market grows, telehealth companies court payers

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Lawsuit challenges CMS nursing home minimum staffing rule

United colonoscopy coverage change 'may cost lives,' doctors say

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Hollywood unions extend contract negotiations for actors

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

hotspot

Louisiana bill approved classifying abortion pills as controlled substances

PBMs are inflating the cost of generic drugs. They must be reined in

National associations that represent hospice owe an apology

Republicans love RFK Jr. What's that tell us about health in 2024?

Beyond aggravation: Constipation is an American epidemic

How to make over

Wikipedia

focus

leisure time

knowledge